Clinical Trial Update: Study Evaluating the Safety and Efficacy of Eribulin Mesilate in Combination With Irinotecan Hydrochloride in Children With Refractory or Recurrent Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating eribulin mesilate with irinotecan in children with refractory or recurrent solid tumors has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ewing Sarcoma
• Non-rhabdomyosarcoma Soft Tissue Sarcoma
• Or Recurrent Solid Tumors
• Rhabdomyosarcoma

Drugs mentioned

• IRINOTECAN HYDROCHLORIDE (irinotecan hydrochloride)
• eribulin mesilate (eribulin mesilate)

Snippet

Sponsor: Eisai Inc. | Conditions: Refractory or Recurrent Solid Tumors, Rhabdomyosarcoma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2022-06-28